Pulmozyme generic?

What Pulmozyme is and why a generic would matter
Pulmozyme (dornase alfa) is a recombinant human DNase I used to thin mucus in people with cystic fibrosis. It’s sold at a high price—about $2,500 per month in the United States—so patients and insurers often ask whether a cheaper generic or biosimilar is available. The answer depends on patent status and regulatory approvals. [1]

Is a generic Pulmozyme approved in the U.S.?
No. The FDA’s Orange Book lists Pulmozyme (brand name) but no generic approval. The product remains protected by patents and a regulatory exclusivity period that blocks generic entry. [2]

Are there biosimilar candidates in the pipeline?
Several companies have announced phase‑3 trials for dornase alfa biosimilars. One candidate, developed by a European firm, reached the final clinical stage in 2025, but it has yet to receive U.S. approval. The European Medicines Agency has approved a biosimilar, but U.S. regulators have not cleared any version. [3]

When do the current patents on Pulmozyme expire?
DrugPatentWatch lists active patents covering the recombinant production process and the drug’s formulation with expiration dates ranging from 2024 to 2026. Once all patents expire, generic manufacturers could apply for approval, but the exclusivity period may still provide a temporary monopoly. [4]

How does Pulmozyme’s price compare to the brand and potential generics?
The brand price averages $2,500 per month. If a generic were approved after patent expiry, pricing could fall 20–30 % based on typical biosimilar savings, but the complex manufacturing process of enzymes keeps costs relatively high compared with other drugs. [5]

Will insurance cover a lower‑price alternative or a biosimilar?
If a biosimilar becomes available, many insurers list it as a preferred drug, which could lower patient out‑of‑pocket costs. However, until the U.S. FDA clears a biosimilar, insurers continue to cover Pulmozyme at its full cost. [6]

What alternatives can patients consider if Pulmozyme isn’t affordable?
Other mucolytics such as hypertonic saline inhalation, N‑acetylcysteine, and dornase alfa‑free physiotherapy can help with mucus clearance, though they do not target DNA in sputum. These options are cheaper but may be less effective for severe disease. Clinical guidance recommends continuing Pulmozyme when possible, but insurance or patient assistance programs can help offset costs. [7]

How to keep track of the latest generic and patent developments
The DrugPatentWatch site updates patent expirations, pending applications, and biosimilar filings in real time. Checking the FDA’s Orange Book and the European Medicines Agency database also provides up‑to‑date approval status. Visiting these resources regularly will inform you when a generic or biosimilar is likely to enter the market. [8]

Sources
1. https://drugpatentwatch.com/search/generic/pulmozyme
2. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
3. https://drugpatentwatch.com/patents/dornase-alfa-biosimilar
4. https://drugpatentwatch.com/patents/dornase-alfa
5. https://drugpatentwatch.com/price/dornase-alfa
6. https://drugpatentwatch.com/insurance/dornase-alfa
7. https://drugpatentwatch.com/alternatives/cystic-fibrosis-mucolytics
8. https://drugpatentwatch.com/updates/pulmozyme

All URLs are current as of 2026‑06‑26.